Updated from 8:11 a.m. EDTEli Lilly ( LLY) Thursday reported double-digit sales growth for the sixth straight quarter, thanks to both new and established drugs. Indianapolis-based Lilly said net income fell 5% to $656.9 million, or 60 cents a share, vs. $692.2 million, or 64 cents a share in the year-ago period. But excluding charges, profit rose 7% to $738.7 million, or 68 cents a share. The consensus estimate was for net income of $735.4 million, or 68 cents a share, on revenue of $3.4 billion, according to Thomson First Call. Revenue rose to $3.56 billion, vs. $3.09 billion a year ago. In terms of future guidance, Lilly expects EPS of 67 cents to 68 cents in the third quarter and $2.80 to $2.85 for the full year, excluding charges. The consensus estimates are 71 cents and $2.82, respectively. Sales of Zyprexa, an anti-psychotic, led the way in the quarter, racking up $1.21 billion in sales, up 16% from a year ago. International sales jumped 31%. Lilly's group of diabetes treatments rose 5% from the year-ago period to $674.9 million. The company said newer products, including its erectile dysfunction drug Cialis, contributed $350.4 million in sales in 2004, accounting for 10% of total revenue. Lilly is widely considered to have one of the best product pipelines in the industry. Total worldwide sales for Cialis, the impotence drug that reached the U.S. market in late November, grew to $137.2 million, up from $37.4 million a year ago and $108.3 million in the first quarter. Cialis was developed by Icos ( ICOS) and is marketed in North American and European markets by a joint venture of the two companies and in other markets by Lilly. U.S. sales hit $50.8 million in the April-June period.